Expression and activity of paraoxonase 1 in human cataractous lens tissue

Free Radical Biology and Medicine

Volumn 46, Issue 8, 2009, Pages 1089-1095

  Hashim, Zehra ^a   Ilyas, Amber ^a   Saleem, Ammara ^a   Salim, Asmat ^a   Zarina, Shamshad ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Aging; Antioxidant; Cataract; Diabetes; Free radicals; Lens; Paraoxonase expression; Three dimensional structure prediction

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLDIALKYLPHOSPHATASE 3; ARYLESTERASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; FEMALE; GENE EXPRESSION; GLYCATION; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE;

AGED; AGING; ARYLDIALKYLPHOSPHATASE; CATARACT; DIABETES MELLITUS, TYPE 2; ESTERASES; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; LENS, CRYSTALLINE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; MODELS, CHEMICAL; OXIDATIVE STRESS; SUBSTRATE SPECIFICITY;

EID: 63049126877     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.01.012     Document Type: Article

References (50)

1. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
2. Draganov D.I., and La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedebergs Arch. Pharmacol. 369 (2004) 78-88
3. Cronin S., Greenway M.J., Prehn J.H., and Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 78 (2007) 984-986
4. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parma S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
5. Li H.L., Liu D.P., and Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J. Mol. Med. 81 (2003) 766-779
6. Liu Y., Mackness B., and Mackness M. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic. Biol. Med. 45 (2008) 743-748
7. Sorenson R.C., Primo-Parmo S.L., Kuo C.L., Adkins S., Lockridge O., and La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7187-7191
8. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., and La Du B.N. Human serum paraoxonase (pon1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
9. Shih D.M., Gu L., Xia Y.-R., Navab M., Li W.-F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
10. Rodrigo L., Mackness B., Durrington P.N., Hernandez A., and Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354 (2001) 1-7
11. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
12. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
13. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 (2005) 1239-1247
14. Upham B.L., and Wagner J.G. Toxicant-induced oxidative stress in cancer. Toxicol. Sci. 64 (2001) 1-3
15. Dhalla N.S., Temsah R.M., and Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18 (2000) 655-673
16. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol. Biol. (Paris) 44 (1996) 57-64
17. Sayre L.M., Smith M.A., and Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8 (2001) 721-738
18. Ozmen B., Ozmen D., Erkin E., Guner I., Habif S., and Bayindir O. Lens superoxide dismutase and catalase activities in diabetic cataract. Clin. Biochem. 35 (2002) 69-72
19. Vinson J.A. Oxidative stress in cataracts. Pathophysiology 13 (2006) 151-162
20. Suryanarayana P., Krishnaswamy K., and Reddy G.B. Effect of curcumin on galactose-induced cataractogenesis in rats. Mol. Vision 9 (2003) 223-230
21. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999) 1-9
22. Hashim Z., and Zarina S. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin. Biochem. 40 (2007) 705-709
23. Reed N.A., Oh D.-J., Czymmek K.J., and Duncan M.K. An immunohistochemical method for the detection of proteins in the vertebrate lens. J. Immunol. Methods 253 (2001) 243-252
24. Gil F., Pla A., Gonzalvo M.C., Hernández A.F., and Villanueva E. Rat liver paraoxonase: subcellular distribution and characterization. Chem. Biol. Interact. 87 (1993) 149-154
25. Zarina S., Zhao H.-R., and Abraham E.C. Advanced glycation end products in human senile and diabetic cataractous lenses. Mol. Cell. Biochem. 210 (2000) 29-34
26. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
27. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
28. Bairoch A., and Apweiler R. The SWISS-PROT protein sequence data bank and its new supplement TREMBL. Nucleic Acids Res. 24 (1996) 21-25
29. Altschul S.F., Madden T.L., Schäffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
30. Sali A., and Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
31. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
32. Salim A., Bano A., and Zaidi Z.H. Prediction of possible sites for post translational modifications in human gamma crystallins: effect of glycation on the structure of human gamma-B-crystallins as analyzed by molecular modeling. Proteins Struct. Funct. Genet. 53 (2003) 162-173
33. http://accelrys.com/. (Date accessed: February 10. 2009)
34. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., and Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419
35. Maiti R., Van Domselaar G.H., Zhang H., and Wishart D.S. SuperPose: a simple server for sophisticated structural superposition. Nucleic Acids Res. 32 (2004) W590-W594
36. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1812-1818
37. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., Miller J.E., Boulton A.J.M., and Durrington P.N. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
38. Sakai T., Matsuura B., and Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern. Med. 37 (1998) 581-584
39. Quemeneur T., Martin-Nizard F., Kandoussi A., Kyndt X., Vanhille P., Hachulla E., Hatron P.Y., Fruchart J.C., Duriez P., and Lambert M. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin. Arthritis Rheum. 37 (2007) 149-155
40. Baskol G., Demir H., Baskol M., Kilic E., Ates F., Kocer D., and Muhtaroglu S. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38 (2005) 951-955
41. Baskol G., Karakucuk S., Oner A.O., Baskol M., Kocer D., Mirza E., Saraymen R., and Ustdal M. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 220 (2006) 12-16
42. Dantoine T.F., Debord J., Charmes J.P., Merle L., Marquet P., Lachatre G., and Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9 (1998) 2082-2088
43. Hashim Z., and Zarina S. Antioxidant markers in human senile and diabetic cataractous lenses. J. Coll. Phys. Surg. Pak. 16 (2006) 637-640
44. Donma O., Yorulmaz E., Pekel H., and Suyugul N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr. Eye Res. 25 (2002) 9-16
45. Shamir R., Hartman C., Karry R., Pavlotzky E., Eliakim R., Lachter J., Suissa A., and Aviram M. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic. Biol. Med. 39 (2005) 336-344
46. Marsillach J., Mackness B., Mackness M., Riu F., Beltrán R., Joven J., and Camps J. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45 (2008) 146-157
47. Babizhayev M.A., Deyev A.I., Yermakova V.N., Brikman I.V., and Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R. D. 5 (2004) 125-139
48. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., and La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 (1999) 892-904
49. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., Wong H., and Peters A.L. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320
50. Yeung D.T., Josse D., Nicholson J.D., Khanal A., McAndrew C.W., Bahnson B.J., Lenz D.E., and Cerasoli D.M. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim. Biophys. Acta 1702 (2004) 67-77